ESG Dynamics-Sino Biopharm

Stock Symbol 01177

About Us
R&D
Products
News
Sustainability
Investors
Legel Terms

CN EN

Sustainability

Home >Sustainability >ESG Dynamics

ESG Strategy and Governance
ESG Policies and Commitments
ESG Dynamics
ESG Reports

Edaravone and Sodium Chloride Injection for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Release Date: 2022-01-01

Share:

Previous：Drugs Serve Patients in Developing Countries
Next：Collaborating with Colleges and Universities on Industry-Academia-Research Training for Graduates

About Us: About Sino Biopharm Management Team Major Events

R&D

Products: Innovative Products Oncology Hepatology Respiratory Surgery/Analgesic Others

News

Sustainability: ESG Strategy and Governance ESG Policies and Commitments ESG Dynamics ESG Reports

Investors: Information Disclosure Corporate Governance Presentation Investor FAQs Notices

Legel Terms: Our Culture Human Development Join Us

Contact Us: Beijing Headquarters: 45 Floor, CP Center North Tower, 10 Guanghua Road, Chaoyang District, Beijing, China Tel：(+86)10 59257399 E-mail：info@cppharm.com PR：pr@cppharm.com; Hong Kong Headquarters: Unit 09, 41/F, Office Tower, Convention Plaza, 1 Harbour Road, Wan Chai, Hong Kong Tel：(+852) 2802 9886 E-mail: info@sino-biopharm.com

Complaint and Report: Complaint and Report E-mail：sjjcb@cttq.com

Legal Terms|Contact Us|Privacy Policy

© 2023 Sino Biopharmaceutical Co., Ltd. All rights reserved.

Links: CP Group invoX Pharma Limited CTTQ Pharmaceutical Beijing Tide Pharmaceutical Nanjing Chiatai Tianqing Pharmaceutical LaNova Medicines Limited Jiangsu Chiatai Qingjiang Pharmaceutical Jiangsu Chiatai FenghaiPharmaceutical